Alabama
Hoover; Central Alabama Oncology, LLC
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Alaska
Anchorage; Alaska Clinical Research Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Anchorage; Alaska Clinical Research Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Arizona
Glendale; Palo Verde Hematology/Oncology
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Scottsdale; Mayo Clinic Scottsdale
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Tucson; Arizona Clinical Research Center, Inc.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Arkansas
Fort Smith; St. Edward’s Mercy Medical Center
Summary: VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Little Rock; Arkansas Cancer Research Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
California
Concord; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Concord; Research Center![[*]](../images/newtiny.gif)
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Corona; Compassionate Cancer Care Medical Group, Inc.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Duarte; City of Hope
A Pilot Study to Determine the Reliability of Telomerase RNA Detection in the Expressed Prostatic Secretion of Men Undergoing Prostatic Biopsy in Confirming Cancer Diagnosis
Duarte; City of Hope
SWOG 9346: Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III
Duarte; City of Hope
Long Term Follow Up after Prostate Cancer
Duarte; City of Hope
SWOG S0421: Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
Duarte; City of Hope
Erectile Dysfunction Recovery in Men age
Duarte; City of Hope
Androgen Deprivation and Localized Radiotherapy to Metastases in Patients with Oligometastatic Hormone - Sensitive Prostate Cancer
Duarte; City of Hope
Prostate Cancer Outcomes by Race and Treatment Site
Duarte; City of Hope
Pre-Surgical EPS Biomarkers as Predictors of Recurrence
Duarte; City of Hope
Prostate Cancer Database
Fountain Valley; Research Center
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
Fountain Valley; Compassionate Cancer Care Medical Group, Inc.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Fountain Valley; Pacific Coast Hematology/Oncology Medical Group
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Greenbrae; California Cancer Care
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
La Mesa; Center for Urological Research
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Loma Linda; Loma Linda University
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Los Angeles; Oncology Care Medical Associates
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Los Angeles; Cedars Sinai Medical Center
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Los Angeles; Kenmar Research Institute
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Louisville; James Graham Brown Cancer Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Orange; UC Irvine Medical Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Rancho Mirage; Desert Hematology Oncology Medical Group
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Sacramento; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
San Bernardino; San Bernardino Urology Associates
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
San Bernardino; San Bernardino Urology Associates
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
San Diego; Kaiser Permanente Medical Group Dept. of Oncology Research
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
San Diego; Sharp Healthcare
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
San Diego; Sharp Healthcare
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
San Francisco; California Pacific Medical Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
San Francisco; UCSF Mt. Zion Cancer Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
San Francisco; California Pacific Medical Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
San Mateo; California Cancer Care
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Soquel; Cancer Research & Treatment Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Soquel; Cancer Research & Prevention Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Torrance; Western Clinical Research, Inc.
Attention: Men with Prostate Cancer
Vista; San Diego Cancer Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Colorado
Aurora; University of Colorado Health Science Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Aurora; Cancer Center and Department of Medicine
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Colorado Springs; Cancer Center of Colorado Springs
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Connecticut
Bristol; The Hope Clinic
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Middlebury; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Middlebury; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
New Britain; Urology Center of Grove Hill
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Stamford; Carl & Dorothy Bennett Cancer Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Florida
Aventura; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Aventura; South Florida Medical Research, Inc.
Phase IV, Hormone Refractory Prostate Cancer Study
Aventura; South Florida Medical Research
Phase II, Clinical Trial For Patients with Prostate Cancer or Breast Cancer with Metastatic Disease
Boca Raton; Boca Raton Community Hospital, Inc.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Clearwater; DMI Health Care Group
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Fort Lauderdale; Michael and Dianne Bienes Comprehensive Cancer Center, Holy Cross Hospital
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Gainesville; Gainesville Hematology/ Oncology Associates
A Phase III, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer
Jacksonville; Integrated Community Oncology Network
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Jacksonville; Mayo Clinic Jacksonville
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Jupiter; Jupiter Hematology & Oncology Associates
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Lakeland; Lakeland Regional Cancer Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Miami; Advanced Medical Specialties
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Ocoee; Cancer Centers of Florida
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Port St. Lucie; Hem-Onc. Asc. of the Treasure Coast
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Port St. Lucie; Hematology Oncology Associates of the Treasure Coast
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Sarasota; Florida Urology Specialists
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
St. Petersburg; Advent Clinical Research Centers, Inc.
Male Hot Flash Study
Tallahassee; Southeastern Research Group, Inc.
A Phase III Study of Study Drug on Prolonging Bone Metastasis-Free Survival in Men with Hormone- Refractory Prostate Cancer
Georgia
Atlanta; Winship Cancer Institute, Emory University
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Atlanta; Peachtree Hematology-Oncology Consultants, PC
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Atlanta; Peachtree Hematology & Oncology Consultants, PC
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Atlanta; Emory Winship Cancer Institute
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Decatur; Atlanta VAMC
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Decatur; Atlanta VA Medical Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Macon; Central Georgia Cancer Care, PC
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Tucker; Georgia Cancer Specialists
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Hawaii
Honolulu; Straub Clinic & Hospital
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Idaho
Vincennes; Biomedical Research Alliance of New York
Prostate Cancer - Adults
Illinois
Chicago; University Of Chicago
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Chicago; Univ.of Illinois at Chicago
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Elgin; Sherman Health Systems
ECOG E5805 "A phase I trial of E7389 (Halichondrin B Analog), in patients with metastatic hormone refractory prostate cancer"
Galesburg; Medical & Surgical Specialists
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Peoria; Specialty Care Research
Prostate Cancer Study
Peoria; Specialty Care Research
Prostate Cancer And Hot Flashes
Indiana
Evansville; Welborn Clinic Research Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Fort Wayne; Fort Wayne Medical Oncology/Hematology Inc.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Jeffersonville; Metropolitan Urology, PSC.
Have you been diagnosed with prostate cancer? Has the cancer spread to the bone? Is your PSA rising? If so you may qualify for a clinical research trial for the treatment of bone metastases in men with hormone-refractory prostate cancer.
Louisiana
Lafayette; Louisiana Oncology Associates
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Maryland
Baltimore; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Baltimore; Johns Hopkins Unv. School of Med., Sidney Kimmel Comprehensive Cancer Center
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Baltimore; Johns Hopkins Unv., School of Medicine
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Baltimore; Johns Hopkins University
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Baltimore; The Bunting Blaustein Cancer Research Building
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Frederick; Frederick Memorial Hospital Regional Cancer Therapy Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Frederick; Frederick Memorial Hospital Regional Cancer Therapy Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Michigan
Ann Arbor; General Clinical Research Center University of Michigan
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Detroit; Henry Ford Health System
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Free Soil; West Michigan Regional Cancer and Blood Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Royal Oak; William Beaumont Hospital, Cancer Clinical Trials Office
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Southfield; Newland Medical Associates, P.C
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Minnesota
Chaska; Ridgeview Research
Prostate Cancer
Missouri
St. Louis; Washington University School of Medicine - Barnes Jewish Hospital
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
St. Louis; Hematology Oncology Consultants, Inc.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Montana
Billings; Research Center
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
Billings; Deaconess Billings Clinic
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Billings; Hematology/Oncology Centers of the Northern Rockies, P.C.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Billings; Billings Clinic
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Nebraska
Omaha; University of Nebraska Medical Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Omaha; Omaha VA Medical Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Omaha; University of Nebraska Medical Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Omaha; Hematology & Oncology Consultants, P.C.
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Nevada
Las Vegas; Nevada Cancer Institute
Summary: VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Las Vegas; Sheldon J. Freedman, MD LTD
Prostate Cancer - High Risk, Men Age 18 and Above, Infused Antibody Plus Hormone Therapy Prior to Prostatectomy, 4 Month Research Study
Las Vegas; Sheldon J. Freedman, MD LTD
Prostate Cancer - Prevention of Bone Fractures, Men Age 50 and Above, 2 Year Oral Medication Research Study
Las Vegas; Sheldon J. Freedman, MD LTD
Prostate Cancer - Advanced, Men Age 18 and Above, 12 Week Injected Medication
Las Vegas; Sheldon J. Freedman, MD LTD
Benign Prostatic Hyperplasia (BPH), Men Age 45-75, 4 Month Prostate Injection Research Study
New Hampshire
Lebanon; Dartmouth-Hitchcock Medical Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
New Jersey
Berkeley Heights; Summit Medical Group
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Cherry Hill; The Center for Cancer & Hematologic Disease
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Hackensack; Hackensack University Medical Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Lawrenceville; AdvanceMed Research
Prostate Cancer that requires Hormone therapy.
Lawrenceville; AdvanceMed Research
Do you have Prostate Cancer?
Morristown; Hematology-Oncology Associates of Northern New Jersey
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Newark; New Jersey Medical School
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Voorhees; Delaware Valley Urology, LLC
Have you been diagnosed with Prostate Cancer, Chronic Prostatitis, or Benign Prostatic Hyperplasia (BPH)?
New Mexico
Albuquerque; Urology Group of New Mexico
Low-risk, Localized Prostate Cancer in men who are Candidates for or Undergoing Expectant Management
Albuquerque; Urology Group of New Mexico
A study to treat men with Prostate Cancer without bone metastasis who are on androgen deprivation treatment.
Albuquerque; Urology Group of New Mexico
A study to treat men with Prostate Cancer with bone metastasis who are on androgen deprivation treatment.
Albuquerque; New Mexico Oncology
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Farmington; Research Center
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
New York
Bronx; Research Center
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
Bronx; Jacobi Medical Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Bronx; Biomedical Research Alliance of New York
Montefiore Medical Center is conducting a clinical study to assess the safety and efficacy of an experimental drug in men with advanced prostate cancer.
East Setauket; North Shore Hematology Oncology Associates P.C.
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
New Hyde Park; Biomedical Research Alliance of New York
Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) who have failed Docetaxel-Based Chemotherapy - Adults
New York; Mount Sinai Medical Center
Phase I Trial of Adenovirus- Mediated IL-12 Gene Transduction in Patients with Radiorecurrent Prostate Cancer
New York; Mount Sinai Medical Center
Neoadjuvant/Adjuvant Docetaxel and Estramustine in Combination with Brachytherapy and Three-Dimensional Conformal Radiotherapy
New York; Columbia University
A Phase I trial of combined Taxotere/Estramustine + Mitoxantrone/Prednisone in Hormone Refractory Prostate Cancer
New York; Mount Sinai Medical Center
Docetaxel and Estramustine versus Mitoxantrone and Prednisone for Advanced Hormone Refractory Prostate Cancer, Phase III
Sponsor: CALGB
New York; Mount Sinai Medical Center
A Phase II Study of Weekly Taxol and Estramustine for Treatment of Prostate Cancer Micrometastases after Radical Prostatectomy or Salvage Radiation Therapy
New York; Mount Sinai Medical Center
Diagnosis of Prostate Cancer Using Multigene Expression Signatures
New York; NYU Clinical Cancer Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
New York; Mount Sinai Medical Center
Efficacy of combined prophylactic and on demand Sildenafil usage in potent men undergoing brachytherapy and hormonal therapy for localized prostate cancer.
New York; Columbia University Medical Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
New York; Memorial Sloan-Kettering Cancer Center-Sidney Kimmel Center
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Staten Island; Staten Island Urological Research, P.C.
Prostate Cancer Prevention Clinical Trial
Staten Island; Staten Island Urological Research, P.C.
A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy with Autologous Antigen-Loaded Dendritic Cells For Asymptomatic Metastatic Hormone Refractory Prostate Cancer.
Staten Island; Staten Island Urological Research, P.C.
Prostate Cancer Bone Loss Study.
Staten Island; Staten Island Urological Research, P.C.
Prostate cancer trial
Staten Island; Staten Island Urological Research, P.C.
A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind , Dose-Ranging Clinical Trial To Study The Efficacy And Safety of 5, 15 or 25mg/day CyPat (Cyproterone Acetate) for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients
Staten Island; Staten Island Urological Research, P.C.
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone Refractory Prostate Cancer
Staten Island; Staten Island Urological Research, P.C.
A Phase 3, Randomized, Open-label Study Evaluating DN-101 in Combination with Docetaxel in Androgen Independent Prostate Cancer (AIPC) (ASCENT2)
Staten Island; Staten Island Urological Research, PC
Concerned about bone loss associated with your prostate cancer therapy?
Syracuse; SUNY Upstate Medical University
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Various Cities; Research Center
Prostate Cancer Study CLBH589C2208
North Carolina
Charlotte; Presbyterian Hospital Center for Cancer Research
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Charlotte; Presbyterian Hospital Center for Cancer Research
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Hickory; Northwestern Carolina Hematology Oncology, PA
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Huntersville; Carolina BioOncology Institute, PLLC
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Winston-Salem; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Winston-Salem; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
North Dakota
Bismarck; Odyssey Research
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Bismarck; Odyssey Research
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Bismarck; St. Alexius Medical Center
A research study for prostate cancer patients
Bismarck; Odyssey Research Services
A Prostate Cancer Research Study
Fargo; Dakota Cancer Institute
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Ohio
Canton; Research Center
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
Canton; Gabrail Cancer Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Canton; Gabrail Cancer Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Cleveland; Cleveland Clinic Foundation, Taussig Cancer Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Oklahoma
Oklahoma City; University of Oklahoma
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Oregon
Portland; Research Center
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
Portland; Kaiser Permanente Oncology/Hematology
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Portland; Providence Portland Med. Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Portland; Providence Portland Medical Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Pennsylvania
Altoona; Blair Medical Associates
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
Bala Cynwyd; Urologic Surgery PC
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Hershey; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Hershey; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Kingston; Medical Oncology Associates
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Lancaster; Urological Associates of Lancaster
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Lancaster; Lancaster Cancer Center Ltd.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Philadelphia; Fox Chase Cancer Center
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Pittsburgh; University of Pittsburgh Medical Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
South Carolina
Charleston; Charleston Hematology Oncology
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Greenville; Cancer Centers of the Carolinas
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Tennessee
Chattanooga; Memorial Health Care System
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Memphis; The West Clinic
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Memphis; The West Clinic
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Texas
Amarillo; The Don & Sybil Harrigton Cancer Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Austin; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Austin; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Dallas; Center for Oncology Research & Treatment
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Dallas; Dallas Oncology Consultants
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Dallas; Center Oncology Research & Treatment PA
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Dallas; Urology Specialist & Associates, PA
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Dallas; Mary Crowley Medical Research Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Fort Worth; Research Center
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
Houston; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Prostate
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 Private Capsules In Patients
With Incurable, Stage C Or D Adenocarcinoma Of The Prostate
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Prostate
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 Private Capsules In Combination With Total Androgen Blockade In Patients With Adenocarcinoma Of The Prostate
Houston; Mobley Research Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Houston; Northwest Cancer Center (Administrative Office)
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
San Antonio; Urology San Antonio
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
San Antonio; Urology San Antonio Research, PA
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Tyler; Tyler Cancer Center
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Various Cities; Mobley Research Center
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Utah
Salt Lake City; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Vermont
Bennington; Southwestern Oncology Research Dept.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Virginia
Norfolk; Virginia Oncology Associates
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Washington
Seattle; Research Center
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
Seattle; Virginia Mason Medical Center Urology
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Seattle; Seattle Cancer Care Alliance, Univ. of Washington
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Seattle; Research Site:
A Study of Epothilone D in Patients With Metastatic Prostate Cancer
Seattle; Seattle Cancer Care Alliance
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Seattle; Seattle Cancer Care Alliance
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Tacoma; Research Center
Phase 2 Research Study Investigating the Safety and Effectiveness of ZK-Epothilone in Patients with Metastatic prostate cancer
Wisconsin
Madison; University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Milwaukee; Medical College of Wisconsin
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Various Cities; Research Center
Prostate Cancer Study CLBH589C2208
International
Calgary, Alberta, Canada; Tom Baker Cancer Centre
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Montreal, Quebec, Canada; Centre Hospitalier de L'Universite de Montreal
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Montreal, Quebec, Canada; McGill University
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Montreal, Quebec, Canada; Centre Hospitalier de l'Universite de Montreal
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Sherbrooke, Quebec, Canada; Centre Hospitalier Universite de Sherbrooke
VITAL-2 GVAX ® Immunotherapy for Prostate Cancer Trial (G-0034)
Toronto, Ontario, Canada; Princess Margaret Hospital
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Lyon, France; Research Site:
A Study of Pertuzumab in Patients With Prostate Cancer.
Montpellier, France; Centre Val D'Aurelle-Parc Lamarque
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Paris, France; Hopital Europeen Georges Pompidou
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Villejuif Cedex, France; Institut Gustave Roussy
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Berlin, Germany; Research Site:
A Study of Pertuzumab in Patients With Prostate Cancer.
Parma, Italy; Research Site:
A Study of Pertuzumab in Patients With Prostate Cancer.
Roma, Italy; Research Site:
A Study of Pertuzumab in Patients With Prostate Cancer.
Rome, Italy; Azienda Ospedaliera S. Camillo Forlanini
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Pointe Claire, Quebec; Ultra-Med Inc.
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Sherbrooke, Quebec; Center Hopitalier Universitaire de Sherbrooke
VITAL-1 GVAX® Prostate Cancer Immunotherapy Trial (G-0029)
Barcelona, Spain; Research Site:
A Study of Pertuzumab in Patients With Prostate Cancer.
Valencia, Spain; Research Site:
A Study of Pertuzumab in Patients With Prostate Cancer.
Bristol, United Kingdom; Research Site:
A Study of Pertuzumab in Patients With Prostate Cancer.
Cardiff, United Kingdom; Research Site:
A Study of Pertuzumab in Patients With Prostate Cancer.
Sutton, United Kingdom; Research Site:
A Study of Pertuzumab in Patients With Prostate Cancer.
